| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Chimeric (mouse/human) |
| Target | endoglin |
| Clinical data | |
| Other names | TRC-105 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6420H9922N1718O2010S46 |
| Molar mass | 144808.77 g·mol |
Carotuximab (INN) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer.
This drug was developed by Tracon Pharmaceuticals Inc.
It is at Phase III trials for angiosarcoma.
References
- World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF). WHO Drug Information. 29 (4).
- Statement On A Nonproprietary Name Adopted By The USAN Council - Carotuximab, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |